Glomerulonephritis Treatment Market: Introduction
Glomerulonephritis, also known as Bright’s disease, is a progressive kidney disease that damages the glomeruli—the filtering units of the kidney that create urine as a waste. There are two types of glomerulonephritis, namely acute glomerulonephritis and chronic glomerulonephritis.
The acute glomerulonephritis disease develops suddenly and can be caused by infections, such as strep throat. Acute glomerulonephritis disease can also be caused by infection in the throat or on the skin, and can get better on its own. However, in some cases the kidneys can stop working unless the right treatment is started quickly.
To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=1527
The other causes of acute glomerulonephritis are lupus, Goodpasture’s syndrome, Wegener’s disease, and polyarteritis nodosa. The chronic glomerulonephritis form may develop silently (without symptoms) over several years. It often leads to complete kidney failure. The excessive usage of nonsteroidal anti-inflammatory drugs, such as ibuprofen (Advil) and naproxen (Aleve), increase the risk of glomerulonephritis diseases.
Glomerulonephritis Treatment Market: Drivers and Restraints
The growing prevalence of kidney disorders is expected to be the major factor driving the growth of the glomerulonephritis treatment market over the forecast period. Chronic glomerulonephritis accounts for 13.3% cases of newly diagnosed chronic kidney disease (CKD) in India.
Histological classification is based on different patterns of glomerular injury as seen on light microscopy, immunofluorescence (IF) and electron microscopy. Recently published guidelines by the Kidney Disease Improving Global Outcomes (KDIGO) attempt to unify treatment strategies, which vary among physicians in different regions.
Besides, recent advances in knowledge and understanding of the nature and functional disturbances of acute glomerulonephritis have led to the development of rational and effective therapies.
The glomerulonephritis treatment market is expected to witness significant growth over the forecast period due to increased number of clinical trials for drug development with the support of governmental organizations. Increasing prevalence of acute kidney injury (AKI) and chronic kidney disease is expected to be the major factor driving the growth of the glomerulonephritis treatment market over the forecast period.
For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=1527
However, high cost and less awareness among the general population regarding the treatment for glomerulonephritis are factors expected to restrain the growth of the global glomerulonephritis treatment market over the forecast period.
Glomerulonephritis Treatment Market: Segmentation
Tentatively, the global glomerulonephritis treatment market can be segmented on the basis of drug class, distribution channel, and geography.
Based on drug class, the global glomerulonephritis treatment market is segmented as:
- Alkylating Agents
- Mycophenolic acid
- Monoclonal Antibodies
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Angiotensin Receptor Blockers (ARB)
- Other Immunosuppressants
Based on distribution channel, the global glomerulonephritis treatment market is segmented as:
- Hospital Pharmacies
- Retail Pharmacies
- Private Clinics
Glomerulonephritis Treatment Market: Overview
The global market for acute glomerulonephritis treatment is expected to witness significant growth over the forecast period. As drug-induced nephrotoxicity is observed as a common problem in clinical medicine and the incidence of drug-related acute kidney injury (AKI) is predicted as high as 60%, the demand for biomarkers is expected to be high for acute glomerulonephritis treatment. Besides, various initiatives by the governments in the developing countries, FDA support for the development of biomarkers and increasing demand for personalized medicines are some of the other factors expected to propel the growth of the global glomerulonephritis treatment market.
For entire list of market players, request for TOC here – https://www.factmr.com/connectus/sample?flag=T&rep_id=1527
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583